Literature DB >> 20566410

HIF-1alpha accumulation upregulates MICA and MICB expression on human cardiomyocytes and enhances NK cell cytotoxicity during hypoxia-reoxygenation.

Liang Wei1, Jun Lu, Li Feng, Dan Long, Juan Shan, Shengfu Li, Youping Li.   

Abstract

AIMS: To investigate whether hypoxia-inducible factor (HIF) 1alpha and cyclosporin A (CsA) can regulate MICA/B expression and affect NK cytotoxicity during ischemia/reperfusion (I/R) injury. MAIN
METHODS: We generated an HIF-1alphaDeltaODD-expressing adenovirus which can functionally and steadily express HIF-1alpha during normoxia and transfected human cardiomyocytes (HCMs) to investigate whether HIF-1alpha, as a single factor, can upregulate MICA/B expression. Alternatively, HCMs were treated with HIF-1alpha RNAi or CsA, and then cultured under hypoxia/reoxygenation (H/R) condition to simulate I/R injury in vitro. Cells were collected at different time points and used for studies of gene expression and NK cytotoxicity. KEY
FINDINGS: Expression of MICA/B in HCMs is upregulated through HIF-1alpha overexpression in normoxia, and inhibited by HIF-1alpha RNAi treatment during hypoxia-reoxygenation (H/R). NK cytotoxicity towards HCMs shows a positive correlation with HIF-1alpha expression. Moreover, CsA can inhibit HIF-1alpha and MICB expression but upregulates MICA expression during H/R. SIGNIFICANCE: These findings suggest that proper control of HIF-1alpha expression via CsA dose may be a potential therapeutic approach for avoiding MIC expression, and improving the function and long-term survival of heart allografts. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566410     DOI: 10.1016/j.lfs.2010.05.012

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Differential expression of microRNAs during allograft rejection.

Authors:  L Wei; M Wang; X Qu; A Mah; X Xiong; A G C Harris; L K Phillips; O M Martinez; S M Krams
Journal:  Am J Transplant       Date:  2012-02-02       Impact factor: 8.086

2.  HIF-1α regulated tongue squamous cell carcinoma cell growth via regulating VEGF expression in a xenograft model.

Authors:  Jun Liang; Zhaoqiang Zhang; Lizhong Liang; Yun Shen; Kexiong Ouyang
Journal:  Ann Transl Med       Date:  2014-09

3.  A hypoxia-induced decrease of either MICA/B or Hsp70 on the membrane of tumor cells mediates immune escape from NK cells.

Authors:  Daniela Schilling; Fabian Tetzlaff; Sarah Konrad; Wei Li; Gabriele Multhoff
Journal:  Cell Stress Chaperones       Date:  2014-08-08       Impact factor: 3.667

4.  NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies.

Authors:  Giulia Fregni; Aurélie Perier; Marie-Françoise Avril; Anne Caignard
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

5.  Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.

Authors:  Yan Chen; Hongmei Chen; Yochai Birnbaum; Manjyot K Nanhwan; Mandeep Bajaj; Yumei Ye; Jinqiao Qian
Journal:  Diab Vasc Dis Res       Date:  2017-01-23       Impact factor: 3.291

Review 6.  When a Friend Becomes Your Enemy: Natural Killer Cells in Atherosclerosis and Atherosclerosis-Associated Risk Factors.

Authors:  Maria Teresa Palano; Martina Cucchiara; Matteo Gallazzi; Federica Riccio; Lorenzo Mortara; Gian Franco Gensini; Gaia Spinetti; Giuseppe Ambrosio; Antonino Bruno
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

7.  Tissue-Resident NK Cells Mediate Ischemic Kidney Injury and Are Not Depleted by Anti-Asialo-GM1 Antibody.

Authors:  Francisco Victorino; Dorothy K Sojka; Kelley S Brodsky; Eoin N McNamee; Joanne C Masterson; Dirk Homann; Wayne M Yokoyama; Holger K Eltzschig; Eric T Clambey
Journal:  J Immunol       Date:  2015-10-09       Impact factor: 5.422

8.  NKG2D and its ligands: active factors in the outcome of solid organ transplantation?

Authors:  Beatriz Suárez-Álvarez; Alba Fernández-Sánchez; Antonio López-Vázquez; Eliecer Coto; Francisco Ortega; Carlos López-Larrea
Journal:  Kidney Int Suppl (2011)       Date:  2011-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.